Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed -- Ignore unavailable to you. Want to Upgrade?

To: 10K a day who wrote (245001)	6/11/2003 9:00:45 AM
From: Giordano Bruno	Read Replies (1) \| Respond to of 436258

Merrill analyst sees more gains for biotech (BTK, GILD) By Ted Griffith Biotechnology stocks are poised to build on this year's remarkable gains, according to analyst Eric Ende at Merrill Lynch. The Amex Biotechnology Index (BTK) has soared more than 57 percent from a March low, but Ende is confident there's potential for more upside. In a note to clients Wednesday, he cited anticipated product approvals and the flow of mutual fund money into the sector. He named Gilead Sciences as one of his top picks. Shares of Gilead (GILD) weren't trading in the pre-market. On Tuesday, shares closed up 88 cents to $50.58.